Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Radiation.

University of California San Francisco, San Francisco, California, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:San Francisco, California
Treatments:Chemotherapy, RadiationHospital:University of California San Francisco
Drugs:Journal:Link
Date:Jan 2001

Description:

Patients: This study included 231 patients with newly diagnosed glioblastoma multiforme. (Six patients were later determined to have a gliosarcoma.) The patients were divided into four treatment groups.

1. Group A – Accelerated hyperfractionated irradiation with 44 fractions of 1.6 Gy to a total dose of 70.4 Gy. Administered to 57 patients.
2. Group B – Accelerated hyperfractionated irradiation with 44 fractions of 1.6 Gy to a total dose of 70.4 Gy plus DFMO. Administered to 57 patients.
3. Group C – Standard fractionated irradiation with 33 fractions of 1.8 Gy to a total of 59.4 Gy. Administered to 58 patients.
4. Group D - Standard fractionated irradiation with 33 fractions of 1.8 Gy to a total of 59.4 Gy plus DFMO. Administered to 59 patients.

Treatment: Group D - Standard fractionated irradiation with 33 fractions of 1.8 Gy to a total of 59.4 Gy plus DFMO.

Toxicity: In Group D, there was grade 3 or 4 myelosuppression in one patient and grade 3 ototoxicity in 1 patient. Other toxicities included nausea and diarrhea.

Results: Overall survival for this treatment (Group D) was 44 weeks (i.e. 10.2 months). The authors noted that “no benefit is noted when the polyamine inhibitor DFMO is used concurrently with standard or accelerated fractionated radiation therapy.”

Correspondence: M. Prados, MD





Back